The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Revumenib receives FDA approval for adult and pediatric patients aged ≥1 year with R/R acute leukemia and a KMT2A translocation
On November 15, 2024, the U.S. Food and Drug Administration (FDA) approved revumenib, a menin inhibitor, for the treatment of adult and pediatric patients aged ≥1 year with relapsed/refractory (R/R) acute leukemia with a KMT2A translocation. This approval is based on results from the AUGMENT-101 trial (NCT04065399).1
AUGMENT-101 trial
The AUGMENT-101 trial is a multicenter, single arm, open-label, phase I/II study investigating the safety and efficacy of revumenib in patients with acute leukemia, including those with an MLL/KMT2A gene rearrangement or NPM1 mutation.2 Among the evaluable adult and pediatric patients (≥30 days old) with R/R acute leukemia and a KMT2A translocation (n = 104), the key outcomes were1:
-
The rate of complete remission (CR) plus CR with partial hematologic recovery (CRh) was 21.2% (95% confidence interval [CI], 13.8–30.3), with a median duration of 6.4 months (95% CI, 2.7, not estimable).
-
Among the 22 patients who achieved CR or CRh, the median time to reach CR/CRh was 1.9 months (range, 0.9–5.6 months).
-
Out of 83 patients who required red blood cell (RBC) and/or platelet transfusions at the baseline, 12 became transfusion free during any 56-day post-baseline period.
-
Of the 21 patients independent of both RBC and platelet transfusions at baseline, 10 remained transfusion free during any 56-day post-baseline period.
-
The most common adverse reactions (≥20%) were hemorrhage, nausea, increased phosphate, musculoskeletal pain, infection, increased aspartate aminotransferase, febrile neutropenia, increased alanine aminotransferase, increased intact parathyroid hormone, bacterial infection, diarrhea, differentiation syndrome, electrocardiogram QT prolonged, decreased phosphate, increased triglycerides, decreased potassium, decreased appetite, constipation, edema, viral infection, fatigue, and increased alkaline phosphatase.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
